Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves Shire's triple-bead ADHD therapy

June 23, 2017 7:11 PM UTC

FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients ages 13 and older. The product consists of 3-component, extended release, single-entity mixed amphetamine...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Shire plc